Rocket Lab's SWOT analysis: space firm's stock soars amid challenges

Rocket Lab (RKLB) is experiencing significant growth, with Q1 2025 revenue up 32% year-over-year to $122.6 million and a contracted backlog of $1.1 billion, driven by government contracts and its end-to-end space solutions strategy. The company is progressing with its Neutron rocket development, slated for launch in Q4 2025, and recently acquired Mynaric for $75 million to enhance its capabilities in laser communication; however, the company still has negative EBITDA, and faces execution risks with the Mynaric integration and potential delays in the Neutron program, which could impact future profitability.

Analysis

Rocket Lab (RKLB) is demonstrating significant top-line expansion, evidenced by a 32% year-over-year revenue increase to $122.6 million in Q1 2025 and a 64.98% revenue growth over the last twelve months, supported by a substantial $1.1 billion contracted backlog, of which approximately 56% is expected to be recognized within the next 12 months. This growth is propelled by consistent Electron launch successes, with over 60 successful launches including five in Q1 2025, and strategic moves such as the March 2025 acquisition of Mynaric for an initial $75 million (with a potential additional $75 million), aimed at bolstering laser communication capabilities and establishing a European presence in line with its vertical integration strategy. Despite this revenue momentum and a healthy current ratio of 2.08, the company continues to operate with negative profitability, reporting a Q1 2025 adjusted EBITDA loss of $30 million and an LTM EBITDA of -$173.08 million. Future growth and profitability prospects are heavily reliant on the successful development and timely Q4 2025 launch of its Neutron rocket, a project backed by its inclusion in the U.S. Space Force’s National Security Space Launch program through a $5.6 billion contract, but necessitating approximately $100 million in capital expenditures for the year. Rocket Lab's diversification into space systems, with new products like Star Ray Solar Arrays and MAX software, alongside significant government contracts, such as the $515 million Space Development Agency agreement (of which around 40% is planned for recognition in FY25), underpin its ambition to become an end-to-end space solutions provider. While the stock has shown a remarkable 503.8% return over the past year, it has recently underperformed indices like the S&P Aerospace & Defense ETF (XAR), and InvestingPro data suggests it is overvalued against its Fair Value, though analyst price targets offer a wide range from $16 to $33. The company's CY26E EV/Revenue multiple of 13.3x indicates a market pricing in substantial future growth, balancing the transformative potential of Neutron against key risks including development delays, the financial and operational challenges of integrating Mynaric (which is undergoing restructuring and has production execution issues), and potential shareholder dilution from a possible $500 million ATM equity offering.

Key Decisions for Investors

• Investors should acknowledge Rocket Lab's high-growth potential, highlighted by its $1.1 billion backlog and Q1 2025 revenue of $122.6 million, but must weigh this against current unprofitability, high stock volatility, and an InvestingPro assessment of overvaluation.
• The successful and on-schedule launch of the Neutron rocket, targeted for Q4 2025, and the effective integration of Mynaric are critical catalysts; any delays or execution issues, particularly concerning Mynaric's ongoing restructuring, represent material risks to financial projections and investor sentiment.
• Careful monitoring of capital expenditures, approximately $100 million planned for Neutron development this year, and potential shareholder dilution from the mooted $500 million ATM equity offering is warranted, especially as the company guides for a Q2 2025 adjusted EBITDA loss between $28 million and $30 million.
• Consider the company's CY26E EV/Revenue multiple of 13.3x and the wide analyst price target range ($16 to $33) when evaluating the risk/reward profile, factoring in the stock's recent underperformance against relevant aerospace and defense indices.